Energy News / Shareholders Foundation, Inc.

NASDAQ:TTPH Long Term Shareholder Alert: Investigation of Potential Wrongdoing at Tetraphase Pharmaceuticals Inc

Via: ReleaseWire

Updated 11:30 AM CDT, Thu, October 18,2018

An investigation on behalf of current long term investors in Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) shares over possible breaches of fiduciary duty by certain officers and directors was announced.

San Diego, CA -- (SBWIRE) -- 10/18/2018 -- Certain directors of Tetraphase Pharmaceuticals Inc are under investigation over potential breaches of fiduciary duties.

Investors who are current long term investors in Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm for current long term investors in NASDAQ:TTPH stocks follows a lawsuit filed recently against Tetraphase Pharmaceuticals Inc over alleged securities laws violations. The investigation on behalf of current long term investors in NASDAQ:TTPH stocks, concerns whether certain Tetraphase Pharmaceuticals Inc directors are liable in connection with the allegations made in that lawsuit.

According to the complaint the plaintiff alleges on behalf of persons and/or entities that acquired Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH) securities pursuant and/or traceable to the Company's allegedly false and/or misleading registration statement and prospectus issued in connection with the Company's July 2017 secondary public offering ("SPO" or the "Offering"); and/or acquired Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) securities between March 8, 2017 and February 13, 2018, that the defendants violated Federal Securities Laws.

More specifically, the plaintiff claims that between March 8, 2017 and February 13, 2018, the defendants failed to disclose, that Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) was increasing the patient enrollment in its IGNITE3 trial from 1,000 patients to 1,200 patients to meet the trial's primary endpoints (within the 10% non-inferiority margin), that the enrollment of more patients in the trial indicated that the existing population was inadequate to meet the trial's primary endpoints, and that, as a result of the foregoing, Defendants' statements about Tetraphase's business, operations, and prospects, were materially false and/or misleading and/or lacked a reasonable basis.

Those who purchased shares of Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com

The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, , which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigation, and/or settlements are not filed/reached and/or related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

For more information on this press release visit:
http://www.sbwire.com/press-releases/nasdaqttph-long-term-shareholder-alert-investigation-of-potential-wrongdoing-at-tetraphase-pharmaceuticals-inc-1067939.htm

Media Relations Contact
Michael Daniels
858-779-1554
Email: Click to Email Michael Daniels
Web: http://www.ShareholdersFoundation.com